BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 8769224)

  • 1. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
    Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential role of Neoral in pediatric liver transplantation.
    Whitington PF; Alonso EM; Millis JM
    Transplant Proc; 1996 Aug; 28(4):2267-9. PubMed ID: 8769221
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression.
    Reggiani P; Rossi G; Latham L; Caccamo L; Gatti S; Maggi U; Melada E; Paone G; Doglia M; Vannelli A; Fassati LR
    Transplant Proc; 1998 Aug; 30(5):1855-6. PubMed ID: 9723308
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoral in liver transplantation.
    Jamieson NV; Tan L; Jamieson I; Trull A; Gimson AE; Alexander G; Friend PJ; Calne RY
    Transplant Proc; 1996 Aug; 28(4):2229-31. PubMed ID: 8769207
    [No Abstract]   [Full Text] [Related]  

  • 5. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients.
    Ogino S; Hashikura Y; Katsuyama Y; Ikegami T; Nakazawa Y; Urata K; Terada M; Miyagawa S; Kawasaki S
    Transplant Proc; 2004 Mar; 36(2 Suppl):299S-301S. PubMed ID: 15041357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral.
    Levy GA
    Transplant Proc; 1996 Aug; 28(4):2252-3. PubMed ID: 8769216
    [No Abstract]   [Full Text] [Related]  

  • 8. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
    Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
    Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
    Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
    Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
    [No Abstract]   [Full Text] [Related]  

  • 10. Follow-up after conversion to Neoral in stable heart transplant recipients.
    Pethig K; Geiger M; Korn A; Grote M; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2282-4. PubMed ID: 8769226
    [No Abstract]   [Full Text] [Related]  

  • 11. Experience with neoral cyclosporine through the oral route in liver transplantation.
    Bilbao I; Lazaro JL; Pou L; Charco R; Hildalgo E; Murio E; Margarit C
    Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580
    [No Abstract]   [Full Text] [Related]  

  • 12. Microemulsion cyclosporine with C2 monitoring and tacrolimus in liver transplantation with or without hepatitis C virus infection.
    Jain A
    Liver Transpl; 2006 Oct; 12(10):1452-4. PubMed ID: 17004248
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
    Cooney GF; Lum BL; Meligeni JA; Dunn SP
    Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group.
    Grant D; Rochon J; Levy G
    Transplant Proc; 1996 Aug; 28(4):2232-3. PubMed ID: 8769208
    [No Abstract]   [Full Text] [Related]  

  • 15. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
    Roth D; Miller J
    Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
    Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
    Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
    [No Abstract]   [Full Text] [Related]  

  • 17. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients.
    Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H
    Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation.
    Bilbao I; Pou L; Allende E; Lázaro JL; Charco R; Hidalgo E; Margarit C
    Transplant Proc; 2001 May; 33(3):2124-6. PubMed ID: 11377472
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation.
    Hashikura Y; Kawasaki S; Matsunami H; Terada M; Ikegami T; Nakazawa Y; Watanabe M; Chisuwa H; Kamijima T; Takagi S; Makuuchi M
    Transplant Proc; 1996 Apr; 28(2):1034-5. PubMed ID: 8623218
    [No Abstract]   [Full Text] [Related]  

  • 20. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin.
    Rolles K; Davidson BR; Burroughs AK
    Transplantation; 1999 Oct; 68(8):1195-8. PubMed ID: 10551650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.